JP2009538837A - ヒトおよび動物における病原性障害の予防および処置のためのミクロンサイズの硫黄の使用 - Google Patents
ヒトおよび動物における病原性障害の予防および処置のためのミクロンサイズの硫黄の使用 Download PDFInfo
- Publication number
- JP2009538837A JP2009538837A JP2009512383A JP2009512383A JP2009538837A JP 2009538837 A JP2009538837 A JP 2009538837A JP 2009512383 A JP2009512383 A JP 2009512383A JP 2009512383 A JP2009512383 A JP 2009512383A JP 2009538837 A JP2009538837 A JP 2009538837A
- Authority
- JP
- Japan
- Prior art keywords
- sulfur
- compound
- treatment
- microns
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052717 sulfur Inorganic materials 0.000 title claims abstract description 51
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 239000011593 sulfur Substances 0.000 title claims abstract description 49
- 230000001717 pathogenic effect Effects 0.000 title claims abstract description 31
- 238000011282 treatment Methods 0.000 title claims description 38
- 241001465754 Metazoa Species 0.000 title abstract description 45
- 230000002265 prevention Effects 0.000 title description 3
- 239000002245 particle Substances 0.000 claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 230000001850 reproductive effect Effects 0.000 claims abstract description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 43
- 244000052769 pathogen Species 0.000 claims description 30
- 230000035553 feeding performance Effects 0.000 claims description 11
- 229920005610 lignin Polymers 0.000 claims description 9
- 230000001575 pathological effect Effects 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 33
- 241000282414 Homo sapiens Species 0.000 abstract description 27
- 208000035475 disorder Diseases 0.000 abstract description 25
- 206010035664 Pneumonia Diseases 0.000 abstract description 15
- 238000002560 therapeutic procedure Methods 0.000 abstract description 12
- 239000000203 mixture Substances 0.000 abstract description 10
- YDEXUEFDPVHGHE-GGMCWBHBSA-L disodium;(2r)-3-(2-hydroxy-3-methoxyphenyl)-2-[2-methoxy-4-(3-sulfonatopropyl)phenoxy]propane-1-sulfonate Chemical compound [Na+].[Na+].COC1=CC=CC(C[C@H](CS([O-])(=O)=O)OC=2C(=CC(CCCS([O-])(=O)=O)=CC=2)OC)=C1O YDEXUEFDPVHGHE-GGMCWBHBSA-L 0.000 abstract description 9
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- 201000011510 cancer Diseases 0.000 abstract description 8
- 206010003246 arthritis Diseases 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 201000004681 Psoriasis Diseases 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 3
- 206010025135 lupus erythematosus Diseases 0.000 abstract description 3
- 208000025865 Ulcer Diseases 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000011903 nutritional therapy Methods 0.000 abstract description 2
- 231100000397 ulcer Toxicity 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract 2
- 206010036601 premature menopause Diseases 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 78
- 208000024891 symptom Diseases 0.000 description 16
- 241000282887 Suidae Species 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 12
- 241000283690 Bos taurus Species 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 208000036142 Viral infection Diseases 0.000 description 9
- 230000009885 systemic effect Effects 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 125000004434 sulfur atom Chemical group 0.000 description 8
- 208000035143 Bacterial infection Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 208000022362 bacterial infectious disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 244000144972 livestock Species 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 244000045947 parasite Species 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 241000283903 Ovis aries Species 0.000 description 4
- 208000008469 Peptic Ulcer Diseases 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000009027 insemination Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 206010063409 Acarodermatitis Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000012659 Joint disease Diseases 0.000 description 3
- 208000029578 Muscle disease Diseases 0.000 description 3
- 208000021642 Muscular disease Diseases 0.000 description 3
- 241000204031 Mycoplasma Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241001673669 Porcine circovirus 2 Species 0.000 description 3
- 241000447727 Scabies Species 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 230000035611 feeding Effects 0.000 description 3
- 235000021472 generally recognized as safe Nutrition 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 244000144980 herd Species 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 208000011906 peptic ulcer disease Diseases 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 208000005687 scabies Diseases 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- 208000035484 Cellulite Diseases 0.000 description 2
- 241000223935 Cryptosporidium Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 206010049752 Peau d'orange Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000036232 cellulite Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- JMFRWRFFLBVWSI-NSCUHMNNSA-N coniferol Chemical compound COC1=CC(\C=C\CO)=CC=C1O JMFRWRFFLBVWSI-NSCUHMNNSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000020786 mineral supplement Nutrition 0.000 description 2
- 229940029985 mineral supplement Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 238000004537 pulping Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 description 2
- 208000015891 sexual disease Diseases 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- PTNLHDGQWUGONS-OWOJBTEDSA-N trans-p-coumaryl alcohol Chemical compound OC\C=C\C1=CC=C(O)C=C1 PTNLHDGQWUGONS-OWOJBTEDSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001533384 Circovirus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical group CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229920006125 amorphous polymer Polymers 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- JMFRWRFFLBVWSI-UHFFFAOYSA-N cis-coniferyl alcohol Natural products COC1=CC(C=CCO)=CC=C1O JMFRWRFFLBVWSI-UHFFFAOYSA-N 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000008645 cold stress Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000002478 hand joint Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000002661 proton therapy Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000029119 sperm ejaculation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
Abstract
Description
本願は、2006年6月2日に出願された米国仮特許出願第60/803,731号および2006年6月23日に出願された米国仮特許出願第0/805,619号の利益を請求する。
硫黄は、特に硫化物および硫酸塩中で遊離して存在するか、他の成分と結合して存在する非金属成分である。硫黄は、両アミノ酸のメチオニンとシステインが硫黄を含有することから、食物の絶対的な必要要素である。通常、ほとんどの食物性硫黄は、タンパク質の形態をとる。
体重約65ポンドの肥育用家畜を購入し、175ポンドの体重まで給餌した。給餌時、ならびにストレスおよび/または疾患の発症時には、抗ウイルスワクチン、抗寄生虫治療薬、および抗生物質を投与した。これまでのところ、新たに仕入れた肥育用家畜は以下の健康上の問題を煩っていた:肺炎による死亡を招くウイルス性、寄生虫性および細菌性感染症、下痢による死亡(脱水)を招く細菌性感染症、ならびに動物の全身の健康状態および飼養成績を低下させる寄生虫。ウイルス性および細菌性感染症は、通常、到着後10日に開始し、生存している場合は到着後30日まで持続する。
別の実験では、約250頭のDurrockギルトからなる分娩において、前述の通り、有効量の生物学的平衡化合物を投与した。生物学的平衡化合物の含有割合は、完全試料の0.75%であった。乳飲みブタ用の飼育箱の穏やかな交換パイプライン中の溶液にも生物学的平衡化合物を、1ガロン当たりテーブルスプーン2杯の割合で含ませた。
この実施例では、肺炎に罹患するメスウシに、少なくとも95%の粒子が44ミクロン以下であり、前述の触媒SLSを含む生物学的平衡化合物の飽和溶液を、体重100ポンド当たり8mL投与した。
2005年に、大規模放牧により264頭のウシが生まれた。この年の間に、7頭のウシが下痢で死亡し、6頭が肺炎で死亡し、9頭が両方の疾患により死亡した。全体では264頭の内の22頭のウシが死亡し、死亡率は8.3%であった。
2006年に、子ヒツジを出生する120頭のメスヒツジは、以下の問題を被っていた。前記ヒツジは、腐蹄症、下痢、肺炎、関節炎を患っており、全身の健康状態は悪く、メスヒツジが出生した186頭の内の23頭が死亡した。最も考慮すべき重要な点は、25%以上(すなわちメスヒツジ43頭)が、2本以上の脚の関節に慢性的な関節炎を患っていた点である。これにより治療や取扱いに多大な費用が生じた。2006年に使用した治療は、抗生物質、イボメック、6種混合ワクチン、セレン、およびビタミンEであった。2007年には、3月にメスヒツジが120頭の子ヒツジを出生したが、子ヒツジに下痢や肺炎は見られなかった。メスヒツジにも、関節炎の問題や、妊娠病、肺炎、またはマイコプラズマによる咳が見られず、わずかな腐蹄病が見られ、寒さによるストレスがわずかに見られただけであった。2007年のヒツジ全体の健康状態は優れており、大幅に向上したと考えられた。子ヒツジの死亡率は、2006年の10%から5%未満(すなわち、子ヒツジ5頭)に低下した。2007年で使用した治療は、食物中に1トン当たり50ポンドの生物学的平衡化合物を適切に投与したのみであった。
PCV2とは、ブタにおけるサーコウイルスによる消耗性障害である。ブタの分娩を終えた一腹のブタの子を使用して対照試験を実施した。60頭の離乳を終えたブタに生物学的平衡化合物を投与し、比較として120頭の離乳を終えたブタにウイルスワクチンを接種した。4週間後、生物学的平衡化合物の投与群では死亡が見られず、ワクチン接種群では2頭が死亡した。通常は、治療を行わないと、このウイルスに感染した動物の20%以上が死亡することに留意する。農場経営者により導き出された所見および結論は、ワクチン接種計画よりも生物学的平衡化合物が支持された。経営者によれば、生物学的平衡化合物の投与により、成長速度と全身の健康状態が明らかに良好であるとのことであった。
分娩を終えた500頭の子ブタでは、26頭の出産において25頭の痩せこけた子ブタが記録された。生物学的平衡化合物の適切な投与後には、26頭の出産において痩せこけた子ブタはわずか5〜6頭であった。経営者の談話によると、「これは非常に大きい」とのことである。投与レベルは、全食料配給1000kg当たり7.5kgであった。
10代で脾臓を切除したために免疫不全を患う50歳のヒト男性が慢性肺炎を患っていた。この男性は、39歳から47歳まで、静注電解質補水と抗生物質療法の大量投与を受けるために、平均で年に2.3回通院することになった。この男性が、1日当たり生物学的平衡化合物650mgのカプセルを経口投与で摂取し始めたところ、再発が見られていない。
72歳の高齢の女性が以前に診断を受け、変形性関節症、リウマチ様関節炎および痛風および線維筋痛を患っていた。女性は、非ステロイド性抗炎症薬(NSAID)であるCelebrexの治療を受けていた。
消化性潰瘍を患う62歳の女性が、胃潰瘍のコロニーを治療するために3回の手術を受けた。これらの手術は、広範な種々の抗生物質による治療と同じく失敗であった。
1型糖尿病を患う47歳の男性は、3ヶ月の平均血中グルコール濃度が10.5mg/mL(ミリモル/L)であった。この患者は、多尿症、多飲症、過剰な空腹、視力障害、眠気、吐き気、運動中の耐久力の低下を報告していた。呼吸は深く、速くなることが多く、息のケトンの匂いはマニキュアの除光液に似ていた。この患者は、インスリン療法を受けている間に男性の父親が同じ疾患で死亡したのを目の当たりにしていた。男性は自ら、絶対に必要でない限りは、インスリン療法を受けないことに決めた。2007年8月1日現在、男性は、1型糖尿病に変化が見られなければ、2007年11月1日にインスリン療法を開始するということで主治医と最終的な合意に至った。2007年8月1日に男性は、1日650mgの生物学的平衡化合物の経口カプセルを飲み始めた。2007年11月1日の週に再び主治医に報告した時には、男性の最近3ヶ月の平均血中グルコース血が8.2mg/dL(ミリモル/L)に低下していたことに、主治医は驚きを示した。また、男性は、前記1型糖尿病の身体症状の緩和も報告した。その後、男性の3ヶ月間の平均血中グルコース値は6.0mg/dL(ミリモル/L)まで低下した。これは糖尿病の状態でないと見なされる。さらに、男性は数年ぶりに気分が良いと自ら報告し、上述の1型糖尿病の症状のいずれも見られなかった。すべてのベクトルが非糖尿病の状態に維持され、この患者は、10年間以上の間で最も気分が良いと報告している。
2004年の夏に、71歳の男性が、胃腸管癌(GI癌)と診断された。2004年の夏から2006年の夏まで、この男性は化学療法を受けたが、失敗に終わった。主治医の癌専門医は放射線療法を薦めたが、この患者は放射線療法に自ら反対の意を示した。コンピュータ断層撮影法(CT)や超音波によれば、あらゆる包括的な目的における病状回復の可能性はゼロであると、男性は主治医に言われた。男性は、所定の鎮痛剤を多量に服用し続け、自宅で死ぬことを決意した。2006年7月16日に、1日3回650mgの生物学的平衡化合物のカプセルの投与を開始したところ、この患者は、24時間以内に即座に腹痛が著しく軽減されたと報告した。
数年間狼瘡を患っていた55歳の男性が、2006年9月に1日650mgの前記生物学的平衡化合物の経口摂取を開始した。45日後に血液検査を行ったところ、患者の尿中の狼瘡尿に伴う問題は解消されていると判定された。この患者の投薬および食事における唯一の変更は、食物に前記生物学的平衡化合物を加えただけであった。前記生物学的平衡化合物を毎日摂取してから、今日まで患者は、病気の割には異常なほど良好な健康状態を享受している。
67歳の男性が単純ヘルペスウイルス2型(HSV‐2)を患っていた。HSV‐2は陰部ヘルペスの原因となる。30年以上にわたり、この男性は、皮膚や粘膜内層の小さな水疱を発症するHSV‐2感染症を患っていた。また30年以上にわたり、水疱は10〜15日間持続した。この陰部HSV‐2感染症は重症であり、生殖器部に複数の痛みを伴う水疱が長期間発生していた。このウイルスは、発熱や、排尿時の焼灼痛、脚の付け根のひどい不快感や痒みを引き起こした。30年間の抗ウイルス療法ではHSV‐2感染症を根絶させることができなかったと結論付けられた。しかし、1日3回650mgの前記生物学的平衡化合物の経口カプセルを投与したところ、治療を続けるにつれて、不快感が軽減され、発症期間が10〜15日から1〜2日に短縮された。さらに、発症は、皮膚潰瘍を伴わない生殖器部の皮膚の赤みだけであった。
身体の3分の2に乾癬を患う60歳の男性が、何年にもわたり障害年金を受けていた。1日約1gの前記生物学的平衡化合物を数週間投与したところ、男性は病態の症状が緩和され始めた。
養鶏業者は、7,000匹の若鶏に前記生物学的平衡化合物を1%の割合で42日間投与した。本試験の目的は、飼料を与え、同じ農場から同時に販売される他の群れに比べて、この群れのセルライトの発生率が減少するかどうかを確認することであった。屠殺後、対照群に比べると、セルライトが67%減少したことが判明した。
ある女性が27歳で早期に閉経を迎えた。この女性は甲状腺機能低下症(橋本甲状腺炎)を患っていた。甲状腺機能低下症とは、甲状腺の活性の低下である。女性は、甲状腺ホルモン補充療法であるエルトキシンの治療を受けた。
Claims (11)
- 活性成分として300ミクロン未満の硫黄粒子を含む、医薬組成物。
- 前記活性成分が、300ミクロン未満の硫黄粒子およびリグニン硫酸ナトリウムを含む、請求項1に記載の医薬組成物。
- 前記硫黄粒子が75ミクロン未満である、請求項1または2に記載の医薬組成物。
- 前記硫黄粒子の95〜98%が45ミクロン未満である、請求項3に記載の医薬組成物。
- 医薬組成物を調製する方法であって、有効量の300ミクロン未満の硫黄粒子と適切な賦形剤とを混合する手順を含む、方法。
- 前記賦形剤がリグニン硫酸ナトリウムである、請求項5に記載の方法。
- 前記硫黄粒子が75ミクロン未満である、請求項5に記載の方法。
- 前記硫黄粒子の95〜98%が45ミクロン未満である、請求項5に記載の方法。
- 前記医薬組成物が病原体または病的状態の治療に使用される、請求項5に記載の方法。
- 前記医薬組成物が飼養成績の向上に使用される、請求項5に記載の方法。
- 前記医薬組成物が繁殖成績の向上に使用される、請求項5に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80373106P | 2006-06-02 | 2006-06-02 | |
US80561906P | 2006-06-23 | 2006-06-23 | |
PCT/CA2007/000977 WO2007140588A1 (en) | 2006-06-02 | 2007-06-04 | Pathogenic attenuation via the administration of an equilibiotic compound |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013149285A Division JP2013231073A (ja) | 2006-06-02 | 2013-07-18 | 生物学的平衡化合物の投与による病原体の減衰 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2009538837A true JP2009538837A (ja) | 2009-11-12 |
Family
ID=38800998
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009512383A Pending JP2009538837A (ja) | 2006-06-02 | 2007-06-04 | ヒトおよび動物における病原性障害の予防および処置のためのミクロンサイズの硫黄の使用 |
JP2013149285A Pending JP2013231073A (ja) | 2006-06-02 | 2013-07-18 | 生物学的平衡化合物の投与による病原体の減衰 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013149285A Pending JP2013231073A (ja) | 2006-06-02 | 2013-07-18 | 生物学的平衡化合物の投与による病原体の減衰 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20100172992A1 (ja) |
EP (1) | EP2035018B1 (ja) |
JP (2) | JP2009538837A (ja) |
KR (1) | KR101462090B1 (ja) |
CN (1) | CN101500584B (ja) |
AU (1) | AU2007257286B2 (ja) |
CA (1) | CA2654082C (ja) |
HK (1) | HK1130663A1 (ja) |
MX (1) | MX2008015200A (ja) |
NZ (1) | NZ597657A (ja) |
WO (1) | WO2007140588A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014526511A (ja) * | 2011-09-14 | 2014-10-06 | ヌエヴァス オルタナティヴァス ナチュラルズ,エス.エー.ピー.アイ.デ シー.ブイ. | 高度に生物学的に利用可能なゼロ価硫黄の調製及び組成物並びにその使用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104069089A (zh) * | 2014-06-18 | 2014-10-01 | 上海大学 | 木质素的新用途 |
CA3050761A1 (en) * | 2018-07-26 | 2020-01-26 | Attenubiotics Inc. | Method and use of compositions comprising lignosulfonate and substantially free of elemental sulphur for pathogenic attenuation |
US20200396961A1 (en) * | 2019-06-18 | 2020-12-24 | Susu Pets, Llc | Container for an aqueous composition |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5849607A (ja) * | 1981-09-17 | 1983-03-23 | Mitsuo Matsumoto | 硫黄粉末の微粒化方法 |
JPS6366105A (ja) * | 1986-07-30 | 1988-03-24 | Wada Yoichi | 真核細胞生物群の殺菌機構 |
JPH10158155A (ja) * | 1996-11-29 | 1998-06-16 | Tac Medical Kk | 貼付剤 |
JP2000191520A (ja) * | 1998-12-31 | 2000-07-11 | Kazuo Sakuma | 抗微生物剤 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3326664A1 (de) * | 1982-07-29 | 1984-02-02 | Lilly Industries Ltd., London | Fungizides mittel und verfahren zu seiner herstellung |
CA1339133C (en) * | 1987-03-13 | 1997-07-29 | Rikuo Nasu | Imidazole compounds and biocidal composition comprising the same for controlling harmful organisms |
DE4418976C2 (de) * | 1994-05-31 | 1996-12-12 | Horst Walter Hendricks | Phytotherapeutikum zur Behandlung von Infektionen des Herpes simplex-Virus (Typ 1 und Typ 2) und Verfahren zu seiner Herstellung |
DE19624568A1 (de) | 1996-06-20 | 1998-05-14 | Hans Lufen | Mittel zur topischen Behandlung von Hauterkrankungen |
US5788896A (en) * | 1997-02-27 | 1998-08-04 | Alberta Research Council | Method of producing micron sized sulphur granules |
US5997892A (en) * | 1997-10-09 | 1999-12-07 | Camp; Gary Don | Topical therapeutic composition for and method of treating psoriasis |
EP0983766A1 (de) | 1999-01-20 | 2000-03-08 | Norbert A. Gschwend | Pharmazeutische Zusammensetzung zur Behandlung von rheumatischen Syndromen enthaltend Schwefel, Senfsamen und einen Kupfersalz |
CA2265926C (en) * | 1999-04-08 | 2007-01-02 | Airudin S. Khan | Method of altering plasma homocysteine levels in humans |
DE19934169A1 (de) | 1999-07-21 | 2001-01-25 | Henkel Kgaa | Kosmetische und/oder dermatologische Zubereitungen |
-
2007
- 2007-06-04 US US12/302,945 patent/US20100172992A1/en not_active Abandoned
- 2007-06-04 MX MX2008015200A patent/MX2008015200A/es active IP Right Grant
- 2007-06-04 KR KR1020087032147A patent/KR101462090B1/ko not_active IP Right Cessation
- 2007-06-04 JP JP2009512383A patent/JP2009538837A/ja active Pending
- 2007-06-04 CA CA2654082A patent/CA2654082C/en active Active
- 2007-06-04 AU AU2007257286A patent/AU2007257286B2/en not_active Ceased
- 2007-06-04 EP EP07719893.5A patent/EP2035018B1/en not_active Not-in-force
- 2007-06-04 WO PCT/CA2007/000977 patent/WO2007140588A1/en active Application Filing
- 2007-06-04 CN CN2007800289151A patent/CN101500584B/zh not_active Expired - Fee Related
-
2009
- 2009-09-18 HK HK09108562.2A patent/HK1130663A1/xx not_active IP Right Cessation
-
2012
- 2012-01-18 NZ NZ597657A patent/NZ597657A/xx not_active IP Right Cessation
-
2013
- 2013-07-18 JP JP2013149285A patent/JP2013231073A/ja active Pending
-
2015
- 2015-01-21 US US14/602,004 patent/US20150132390A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5849607A (ja) * | 1981-09-17 | 1983-03-23 | Mitsuo Matsumoto | 硫黄粉末の微粒化方法 |
JPS6366105A (ja) * | 1986-07-30 | 1988-03-24 | Wada Yoichi | 真核細胞生物群の殺菌機構 |
JPH10158155A (ja) * | 1996-11-29 | 1998-06-16 | Tac Medical Kk | 貼付剤 |
JP2000191520A (ja) * | 1998-12-31 | 2000-07-11 | Kazuo Sakuma | 抗微生物剤 |
Non-Patent Citations (5)
Title |
---|
JPN6013001842; 'Sulfur' Pharmaceutical Press 33rd ED., 2002, 1123-1124 * |
JPN6013001843; 'Sulfur revisited' J. Am. Acad. Dermatol. 18(3), 1988, 553-558 * |
JPN6013001844; J. Anim. Sci. 13, 1954, 249-257 * |
JPN6013001846; North Central Regional Extension Publication No.366 , 1997, 1-5 * |
JPN6013001848; Powder Technology 146, 2004, 193-199 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014526511A (ja) * | 2011-09-14 | 2014-10-06 | ヌエヴァス オルタナティヴァス ナチュラルズ,エス.エー.ピー.アイ.デ シー.ブイ. | 高度に生物学的に利用可能なゼロ価硫黄の調製及び組成物並びにその使用 |
Also Published As
Publication number | Publication date |
---|---|
EP2035018B1 (en) | 2014-10-22 |
AU2007257286A1 (en) | 2007-12-13 |
WO2007140588A1 (en) | 2007-12-13 |
CA2654082A1 (en) | 2007-12-13 |
US20100172992A1 (en) | 2010-07-08 |
CN101500584A (zh) | 2009-08-05 |
CN101500584B (zh) | 2012-12-12 |
KR101462090B1 (ko) | 2014-11-17 |
KR20090040268A (ko) | 2009-04-23 |
MX2008015200A (es) | 2009-02-17 |
HK1130663A1 (en) | 2010-01-08 |
EP2035018A1 (en) | 2009-03-18 |
AU2007257286B2 (en) | 2013-02-21 |
US20150132390A1 (en) | 2015-05-14 |
JP2013231073A (ja) | 2013-11-14 |
EP2035018A4 (en) | 2009-09-23 |
CA2654082C (en) | 2015-07-28 |
NZ597657A (en) | 2013-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1390049B1 (en) | Compositions for treating animal diseases and syndromes comprising transfer factor | |
AU2002311871A1 (en) | Compositions for treating animal diseases and syndromes | |
CN101934070A (zh) | 一种含有溶菌酶及低聚寡糖的兽用抗菌药物组合及其应用 | |
JP2013231073A (ja) | 生物学的平衡化合物の投与による病原体の減衰 | |
JP6444515B2 (ja) | タウリンのコロナウイルス属及び/又はロタウイルス属のウィルスにより引き起こされる疾患の予防及び/又は治療における応用 | |
CN102228462A (zh) | 兽用土青注射液制备方法及临床应用 | |
Jenkins | Diseases of geriatric guinea pigs and chinchillas | |
CN105832759B (zh) | 一种预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病的药物组合物 | |
CN105188721B (zh) | 钨(vi)盐用于治疗非糖尿病哺乳动物的雌性不育症的用途 | |
EP1776956A1 (en) | Preventive and/or therapeutic agent for calcipenia | |
TR201808808T4 (tr) | Geviş getiren hayvanlarda hipokalsemi tedavisi için terkip. | |
Tully Jr | Psittacine therapeutics | |
JP5864807B1 (ja) | 乳牛用飼料及び飼育方法 | |
CN108524494A (zh) | 穿琥宁在制备兽用药物中的应用及穿琥宁兽用药剂 | |
RU2404728C1 (ru) | Способ повышения общей резистентности организма, профилактики и лечения респираторных, желудочно-кишечных и гинекологических заболеваний, профилактики эмбриональной смертности у животных и лекарственное средство для его осуществления | |
CN107281192A (zh) | 一种减轻、治疗及预防类风湿性关节炎的组合物 | |
Aini et al. | Case Study: Open Pyometra in a Pomeranian Dog at INI Veterinary Service Clinic | |
CN105832714B (zh) | 牛磺酸在预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用 | |
CN109793838A (zh) | 一种防治藏羚羊口炎的膏药制剂及其制备方法 | |
AU2008200364A1 (en) | Compositions for treating animal diseases and syndromes | |
CN112569278A (zh) | 一种治疗犬肠炎型细小病毒的中兽药配方及其制备方法 | |
ITCH | MAC.~ MC. MACRACANTHORHYNCHUS HIRU | |
WILSON | TREATMENT OF POSTOPERATIVE PARATHYROID INSUFFICIENCY WITH DISSOLVED CALCIUM LACTATE | |
Jehee | Bart Engelen, DVM Nathalie Jehee, DVM Kim van Dinther, DVM Original author: Ellis Draaijer, DVM | |
CZ2005391A3 (cs) | Roztok pro zvířata s L-glutaminem s rehydratačním účinkem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110506 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130118 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130403 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130410 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130718 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131031 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140120 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140127 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140730 |